CA3072389C - Bêta-2-agoniste sélectif pour le traitement de la maladie de von hippel-lindau - Google Patents

Bêta-2-agoniste sélectif pour le traitement de la maladie de von hippel-lindau

Info

Publication number
CA3072389C
CA3072389C CA3072389A CA3072389A CA3072389C CA 3072389 C CA3072389 C CA 3072389C CA 3072389 A CA3072389 A CA 3072389A CA 3072389 A CA3072389 A CA 3072389A CA 3072389 C CA3072389 C CA 3072389C
Authority
CA
Canada
Prior art keywords
adrenergic receptor
day
cells
ici
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3072389A
Other languages
English (en)
Other versions
CA3072389A1 (fr
Inventor
Luisa Maria Botella Cubells
Virginia Albinana Diaz
Karina VILLAR GOMEZ-DE LAS HERAS
Original Assignee
Alianza Espanola De Familias De Von Hippel Lindau Vhl
Consejo Superior de Investigaciones Cientificas CSIC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alianza Espanola De Familias De Von Hippel Lindau Vhl, Consejo Superior de Investigaciones Cientificas CSIC filed Critical Alianza Espanola De Familias De Von Hippel Lindau Vhl
Priority claimed from PCT/EP2018/071220 external-priority patent/WO2019030151A1/fr
Publication of CA3072389A1 publication Critical patent/CA3072389A1/fr
Application granted granted Critical
Publication of CA3072389C publication Critical patent/CA3072389C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention concerne l'utilisation d'un antagoniste sélectif du récepteur 2 adrénergique pour le traitement et la prévention d'une tumeur chez un patient atteint du syndrome de von Hippel-Lindau. En particulier, l'invention concerne l'utilisation d'un dérivé d'alcanolamine ou d'un sel d'addition d'acide pharmaceutiquement acceptable de celui-ci pour le traitement et la prévention d'un hémangioblastome chez des patients atteints de syndrome de VHL.
CA3072389A 2017-08-07 2018-08-06 Bêta-2-agoniste sélectif pour le traitement de la maladie de von hippel-lindau Active CA3072389C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP201731019 2017-08-07
ES201731019 2017-08-07
PCT/EP2018/071220 WO2019030151A1 (fr) 2017-08-07 2018-08-06 Composés pour le traitement de la maladie de von hippel-lindau

Publications (2)

Publication Number Publication Date
CA3072389A1 CA3072389A1 (fr) 2019-02-14
CA3072389C true CA3072389C (fr) 2025-12-02

Family

ID=

Similar Documents

Publication Publication Date Title
Takasu et al. Effect of (R)-2-(2-aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl) amino] ethyl} acetanilide (YM178), a novel selective β3-adrenoceptor agonist, on bladder function
US9421208B2 (en) Methods for the treatment of solid tumors
CN103347517B (zh) 治疗帕金森病中运动障碍的d3多巴胺受体激动剂
CN104093402A (zh) Rtk抑制剂与抗雌激素的组合及其治疗癌症的应用
US20160101090A1 (en) Inhibition of trk kinase mediated tumor growth and disease progression
JP2015525063A (ja) 低酸素状態に基づくｈｓｐ９０インヒビターでの治療のための被験者の予備選択
JP2024521788A (ja) 併用療法
US20220047546A1 (en) Combination cancer therapies
JP2009521470A (ja) シヌクレイン障害の治療
CA3072389C (fr) Bêta-2-agoniste sélectif pour le traitement de la maladie de von hippel-lindau
KR20140032916A (ko) 에틸（２―메틸―３―｛（Ｅ）―［（나프타［２，１―ｂ］퓨란―２―일카보닐）하이드라조노］메틸｝―1Ｈ―인돌―1―일）아세테이트, 이의 유사체를 유효성분으로 포함하는 암 예방 및 치료용 조성물
US11730707B2 (en) Compounds for treating von Hippel-Lindau disease
CN106243096B (zh) 三环类药物的新用途
CN107921105B (zh) Il-8抑制剂用于治疗某些泌尿疾病的用途
Botella et al. Compounds for treating von Hippel-Lindau disease
US12396990B2 (en) Application of 5-hydroxytryptamine receptor 1A in preparing drug for portal hypertension
JP7746157B2 (ja) 膠芽腫の治療および予防
EA044366B1 (ru) Соединения для лечения болезни фон гиппеля-линдау
CN101827816B (zh) Trpv1介导性疾病治疗剂
WO2019212933A1 (fr) Compositions et méthodes pour le traitement de cellules tumorales sénescentes
JP6630285B2 (ja) Ｅｒｇ発癌遺伝子陽性癌のための新規阻害剤
KR20250002214A (ko) Sos1 억제제 및 mek 억제제를 포함하는 병용 요법
US20150065486A1 (en) Methods for treating polycystic kidney disease
KR101599259B1 (ko) 혈관 신생작용 관련 질환 치료를 위한 HIF-1α 저해 화합물
Sánchez-Puelles et al. Treatment and prevention of glioblastoma